HealthTech Innovation Days Announce Details of Conference Program & Attendees
With strong support from the healthtech ecosystem shown by sponsors renewing their participation from last edition and additional newcomers eager to participate to exchanges with a view to bringing therapeutic solutions under development to market more quickly for the benefit of all patients
Paris, France, September 9, 2020 – HealthTech Innovation Days (HTID®), a forum aimed at driving and fostering collaborations within the international healthcare ecosystem, announced details of the program and the status of registrations of its upcoming conference, which will be held on October 5th and 6th in Paris and online.
So far, more than 100 European healthtech companies and 200+ investors from all around the world (Europe, North America, Asia, Middle East, Australia …), including Bain Capital Public Equity, Andreessen Horowitz, Battery Ventures together with more than 15 pharmaceutical companies represented by their Business Development and Corporate Venture Departments have already registered to attend. This will ensure appropriate private meetings to happen during HTID.
The tight program focusing on the economic impact of Covid-19 on the healthcare ecosystem will illustrate the positive measures that continue to take place within the industry. It will also cover discussions on how to ensure efficient corporate governance in innovative biotech firms and expand financing possibilities to support growth. A dedicated section will address scientific trends and perspectives in Cellular therapy & Gene therapy. This program will spread the word widely, to leaders in health technology, international pharmaceutical companies, investors, key opinion leaders, and patient associations. Please find the full program here.
HTID, which is creating a new culture of innovation through collaboration, has also announced a list of its participating sponsors, which include leading pharmaceutical companies: Amgen, Bristol Myers Squibb, Ipsen, Pfizer, Sanofi, Servier; actors in the healthtech industry: BDC, Dechert, Financière Arbevel, Invest Securities, Sofinnova Partners and institutional partners: BPIfrance, Euronext, LEEM (Les Entreprises du Médicament).
The event, which is held by HealthTech For Care and co-organized with EIT Health, will build on the great success of last year’s conference. Part of this co-organisation, HealthTech For Care is very proud to join EIT Health as Network member.
“More than ever, it is essential to strengthen the support available for health innovation. To do so, we are holding this event with a rich and varied program, attended by an impressive pool of investors and SMEs. Furthermore, we are officially launching the Venture Centre of Excellence, a public-private co-investment program developed by EIT Health and the European Investment Fund, at the event. By bringing such key actors together, we are confident that we will concretely further the successful development of European and international healthcare innovation.” said Jean-Marc Bourez, Managing Director of EIT Health France.
“The objective of HTID is to advance and accelerate the development of healthcare solutions for patients in need. With the help of these sponsors and global partners, we will be able to move forward with this important gathering and accomplish our mission during a time when innovative solutions are most needed.” said Maryvonne Hiance, President of HealthTech For Care.
For more information, please visit: http://www.htid-paris.com.
The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.
About EIT Health
EIT Health is a network of best-in-class health innovators including approximately 150 partners and is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. We collaborate across borders to deliver new solutions that can enable European citizens to live longer, healthier lives. As Europeans tackle the challenge of increasing chronic diseases and multi-morbidity, and seek to realise the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market. EIT Health addresses these needs. We connect all relevant healthcare players across European borders – making sure to include all sides of the “knowledge triangle”, so that innovation can happen at the intersection of research, education and business for the benefit of citizens.
EIT Health: Together for healthy lives in Europe.
For more information visit: www.eithealth.eu
The HealthTech Innovation Days aim to drive and foster collaborations within the European healthcare ecosystem. This second edition held by HealthTech For Care, an endowment fund launched by France Biotech, and co-organised with EIT Health, will accelerate patient access to healthcare solutions and contribute to building a stronger ecosystem. This symposium features private meetings between innovative European HealthTech companies, pharmaceutical companies, life sciences-specialized investors, healthcare experts, KOLs and institutional representatives. In addition to the ongoing private meetings, attendees can expect roundtables focused on critical economic and political issues that impact health technology developments. The HealthTech Innovation Days are intended for publicly listed companies whose market capitalization is at least €20 million, or for privately held biotech firms whose drug candidates are currently undergoing late Phase I studies. For MedTech companies, medical devices must have already obtained the CE mark in Europe or FDA approval in the United States. Details of the roundtables will be announced in the coming weeks. HTIDÒ 2020 will be held on October 5 & 6 in Paris. http://www.htid-paris.com/